$2.80-3.4%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $59M to $60M for Fiscal year 2026 — up 12.6% on a year earlier
Just reported
From Apyx Medical Corp's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$14M
+9.0% y/y
+1.1% q/q
Guided
—
No guide given
Actual
-$571K
Guided
—
No guide given
Full year 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $14M | $12.9M | +8.95% |
| Profit | -$1.8M | -$2M | +10.03% |
| Free Cash Flow | -$1.9M | -$4.1M | +53.17% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Apyx Medical Corp reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We are pleased to report 17% growth in our Surgical Aesthetics business for the quarter, reflecting continued adoption of AYON and the progress we are making in executing our commercial strategy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Body Contouring System™ : AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Apyx Medical Corp’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.